Work

Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.5009

Authors: Robert J. Motzer, Toni K. Choueiri, David F. McDermott, Thomas Powles, Jin Yao, Ron Ammar, Simon Papillon-Cavanagh, Shruti S. Saggi, Brent M. McHenry, Petra Ross-Macdonald, Megan Wind-Rotolo

Institutions: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3032638307

Cites:

Cited by: 44

Related to: 10